These findings shed light on the comprehensive understanding of how BAF60c contributes to maintaining VSMC homeostasis and indicate that promoting or preserving VSMC resistance to pathologic cues by modulating epigenetic modifications mediated by the BAF60 family may eventually lead to pharmacological interventions for AAA and other cardiovascular diseases. This evidence concerns the gene SMARCD3 and cardiovascular disorder.